BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...Institute for Gene Therapy spinout Genespire Inc. named Jörn Aldag chairman. He is CEO of Hookipa...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...human antibodies cannot bind,” ExeVir CEO Torsten Mummenbrauer told BioCentury. Mummenbrauer held BD roles at Hookipa...
BioCentury | Oct 15, 2019
Emerging Company Profile

Abalos’ arena: planning to upstage oncolytic viruses

...company is using arenaviruses to treat cancer, Hookipa Pharma Inc. A Phase I/II trial for Hookipa’s...
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

...plc (LSE:GSK; NYSE:GSK). While at GSK, he co-discovered the HIV antiviral Tivicay dolutegravir. Immunotherapy company Hookipa...
...Muscular Dystrophy Association. BioCentury Staff Passage Bio Inc. Novartis AG Hisamitsu Pharmaceutical Co. Inc. Illumina Inc. CureDuchenne Neurogene Inc. Artios Pharma Ltd. HemoShear Therapeutics LLC Hookipa...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...5/7/19 $70.0 $179.2 $133.8 -25% Turning Point Therapeutics Inc. (NASDAQ:TPTX) 4/18/19 $191.5 $536.3 $1,269.8 137% Hookipa...
BioCentury | Apr 18, 2019
Financial News

Hookipa raises $84M in IPO

...at the bottom of its range and selling fewer shares than the company had hoped. Hookipa...
...$355.7 million. If it had sold 6.7 million shares at the midpoint of its range, Hookipa...
..."Hookipa Proposes IPO as its Cancer Vaccines Head Towards the Clinic" ). Baker Brothers was Hookipa's...
BioCentury | Apr 11, 2019
Financial News

Hookipa would raise $101M if IPO prices at midpoint

...Infectious disease and cancer vaccine company Hookipa proposed to sell 6.7 million shares at $14-$16 in...
...to a prospectus for the offering. If priced at the midpoint of the proposed range, Hookipa...
...million. The company first proposed to raise $86.3 million in the IPO in March (see "Hookipa...
BioCentury | Mar 22, 2019
Financial News

Hookipa proposes IPO as its cancer vaccines head towards the clinic

...company Hookipa proposed Friday to raise up to $86.3 million in an IPO on NASDAQ. Hookipa...
...developing vaccines using its VaxWave and TheraT viral vector platforms, both of which are arenavirus-based. Hookipa's...
...CMV glycoprotein B. The company is also developing HB-201 and HB-202 to treat HPV-positive cancers. Hookipa...
BioCentury | Mar 1, 2019
Financial News

Hookipa raises $37.4M series D

...is developing a pipeline of vaccines based on its VaxWave and TheraT viral vector platforms. Hookipa's...
...undisclosed size (see "Gilead, Hookipa in Vector Deal for HBV and HIV" ). Aldag said Hookipa...
...C round that included Gilead (see "Clinical Cash" ). Hookipa Pharma Inc. (New York, N.Y.) Paul Bonanos Hookipa...
BioCentury | Feb 26, 2019
Financial News

Hookipa seeking clinical progress with $37.4M series D round

...is developing a pipeline of vaccines based on its VaxWave and TheraT viral vector platforms. Hookipa's...
...oncology candidates HB-201 and HB-202 to treat HPV-positive cancers; CEO Jörn Aldag told BioCentury that Hookipa...
...undisclosed size (see "Gilead, Hookipa in Vector Deal for HBV and HIV" ). Aldag said Hookipa...
Items per page:
1 - 10 of 29
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...Institute for Gene Therapy spinout Genespire Inc. named Jörn Aldag chairman. He is CEO of Hookipa...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...human antibodies cannot bind,” ExeVir CEO Torsten Mummenbrauer told BioCentury. Mummenbrauer held BD roles at Hookipa...
BioCentury | Oct 15, 2019
Emerging Company Profile

Abalos’ arena: planning to upstage oncolytic viruses

...company is using arenaviruses to treat cancer, Hookipa Pharma Inc. A Phase I/II trial for Hookipa’s...
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

...plc (LSE:GSK; NYSE:GSK). While at GSK, he co-discovered the HIV antiviral Tivicay dolutegravir. Immunotherapy company Hookipa...
...Muscular Dystrophy Association. BioCentury Staff Passage Bio Inc. Novartis AG Hisamitsu Pharmaceutical Co. Inc. Illumina Inc. CureDuchenne Neurogene Inc. Artios Pharma Ltd. HemoShear Therapeutics LLC Hookipa...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...5/7/19 $70.0 $179.2 $133.8 -25% Turning Point Therapeutics Inc. (NASDAQ:TPTX) 4/18/19 $191.5 $536.3 $1,269.8 137% Hookipa...
BioCentury | Apr 18, 2019
Financial News

Hookipa raises $84M in IPO

...at the bottom of its range and selling fewer shares than the company had hoped. Hookipa...
...$355.7 million. If it had sold 6.7 million shares at the midpoint of its range, Hookipa...
..."Hookipa Proposes IPO as its Cancer Vaccines Head Towards the Clinic" ). Baker Brothers was Hookipa's...
BioCentury | Apr 11, 2019
Financial News

Hookipa would raise $101M if IPO prices at midpoint

...Infectious disease and cancer vaccine company Hookipa proposed to sell 6.7 million shares at $14-$16 in...
...to a prospectus for the offering. If priced at the midpoint of the proposed range, Hookipa...
...million. The company first proposed to raise $86.3 million in the IPO in March (see "Hookipa...
BioCentury | Mar 22, 2019
Financial News

Hookipa proposes IPO as its cancer vaccines head towards the clinic

...company Hookipa proposed Friday to raise up to $86.3 million in an IPO on NASDAQ. Hookipa...
...developing vaccines using its VaxWave and TheraT viral vector platforms, both of which are arenavirus-based. Hookipa's...
...CMV glycoprotein B. The company is also developing HB-201 and HB-202 to treat HPV-positive cancers. Hookipa...
BioCentury | Mar 1, 2019
Financial News

Hookipa raises $37.4M series D

...is developing a pipeline of vaccines based on its VaxWave and TheraT viral vector platforms. Hookipa's...
...undisclosed size (see "Gilead, Hookipa in Vector Deal for HBV and HIV" ). Aldag said Hookipa...
...C round that included Gilead (see "Clinical Cash" ). Hookipa Pharma Inc. (New York, N.Y.) Paul Bonanos Hookipa...
BioCentury | Feb 26, 2019
Financial News

Hookipa seeking clinical progress with $37.4M series D round

...is developing a pipeline of vaccines based on its VaxWave and TheraT viral vector platforms. Hookipa's...
...oncology candidates HB-201 and HB-202 to treat HPV-positive cancers; CEO Jörn Aldag told BioCentury that Hookipa...
...undisclosed size (see "Gilead, Hookipa in Vector Deal for HBV and HIV" ). Aldag said Hookipa...
Items per page:
1 - 10 of 29